PMID-sentid Pub_year Sent_text comp_official_name comp_offsetprotein_name organism prot_offset 35609673-3 2022 RLS can generally be well treated with medications such as alpha-2-delta calcium channel ligands (A2Ds) gabapentin, pregabalin, gabapentin enacarbil or, if these are poorly tolerated or lack efficacy, dopamine agonists (DAs), pramipexole, ropinirole or rotigotine. Pramipexole 226-237 RLS1 Homo sapiens 0-3 31008016-2 2019 Pramipexole is a small molecule used in the treatment of idiopathic and uremic RLS. Pramipexole 0-11 RLS1 Homo sapiens 79-82 31008016-6 2019 MATERIALS AND METHODS: Our patient was a 63-year-old man on chronic HD for 5 years who had been treated uneventfully with oral pramipexole for uremic RLS since then. Pramipexole 127-138 RLS1 Homo sapiens 150-153 27958259-1 2017 Acute hyperkinesia after discontinuation of tramadol in a patient with chronic pain using citalopram and pramipexole for restless legs syndrome (RLS) has not been reported. Pramipexole 105-116 RLS1 Homo sapiens 145-148 28845959-11 2017 The main pharmacologic options for RLS management are dopaminergic agonists (eg, pramipexole and ropinirole); gabapentinoids also are good options. Pramipexole 81-92 RLS1 Homo sapiens 35-38 28818004-4 2017 Augmentation, which refers to a paradoxical treatment-related increase in RLS symptoms, has been associated with all three dopamine agonists approved for the treatment of RLS - rotigotine, pramipexole, and ropinirole. Pramipexole 189-200 RLS1 Homo sapiens 74-77 27958259-8 2017 Sudden discontinuation of tramadol in a patient under pramipexole for RLS may cause severe, choreatic hyperkinesias for hours, which immediately resolve upon intravenous fentanyl. Pramipexole 54-65 RLS1 Homo sapiens 70-73 27958259-9 2017 In patients under pramipexole for RLS and tramadol and fentanyl for chronic pain, sudden discontinuation of tramadol should be avoided to prevent induction of restless body syndrome. Pramipexole 18-29 RLS1 Homo sapiens 34-37 23950645-2 2013 Pramipexole, a potent dopamine D2/3 agonist, is recommended as "effective" in the short-term and "possibly effective" in the long-term treatment of primary RLS in the European guidelines on management of RLS. Pramipexole 0-11 RLS1 Homo sapiens 156-159 23950645-3 2013 In this meta-analysis, we summarized the efficacy and tolerability of pramipexole in treatment for primary RLS. Pramipexole 70-81 RLS1 Homo sapiens 107-110 23950645-4 2013 Results of this meta-analysis showed a favorable effect of pramipexole versus placebo on RLS symptoms (mean change on International RLS Study Group Rating Scale [IRLS] score: mean difference [MD] = -5.96; 95% confidence interval [CI]: -7.79 to -4.41, P < 0.00001) and sleep quality (pooled standard mean difference [SMD] = -0.48, 95% CI: -0.61 to -0.35, P < 0.00001). Pramipexole 59-70 RLS1 Homo sapiens 89-92 23950645-4 2013 Results of this meta-analysis showed a favorable effect of pramipexole versus placebo on RLS symptoms (mean change on International RLS Study Group Rating Scale [IRLS] score: mean difference [MD] = -5.96; 95% confidence interval [CI]: -7.79 to -4.41, P < 0.00001) and sleep quality (pooled standard mean difference [SMD] = -0.48, 95% CI: -0.61 to -0.35, P < 0.00001). Pramipexole 59-70 RLS1 Homo sapiens 132-135 23950645-2 2013 Pramipexole, a potent dopamine D2/3 agonist, is recommended as "effective" in the short-term and "possibly effective" in the long-term treatment of primary RLS in the European guidelines on management of RLS. Pramipexole 0-11 RLS1 Homo sapiens 204-207 22808933-8 2012 Moreover, further studies should investigate the extended-release formulation of ropinirole and pramipexole in RLS patients affected by all day long distressing symptoms. Pramipexole 96-107 RLS1 Homo sapiens 111-114 20965780-0 2011 Randomized trial of pramipexole for patients with restless legs syndrome (RLS) and RLS-related impairment of mood. Pramipexole 20-31 RLS1 Homo sapiens 74-77 20965780-0 2011 Randomized trial of pramipexole for patients with restless legs syndrome (RLS) and RLS-related impairment of mood. Pramipexole 20-31 RLS1 Homo sapiens 83-86 20965780-2 2011 We investigated the change of RLS-related mood impairment during treatment of RLS with pramipexole, a dopamine D(3)/D(2) agonist. Pramipexole 87-98 RLS1 Homo sapiens 30-33 20965780-2 2011 We investigated the change of RLS-related mood impairment during treatment of RLS with pramipexole, a dopamine D(3)/D(2) agonist. Pramipexole 87-98 RLS1 Homo sapiens 78-81 20965780-10 2011 CONCLUSIONS: In patients with RLS-related mood disturbance, pramipexole improved RLS while also improving RLS-related mood impairment. Pramipexole 60-71 RLS1 Homo sapiens 30-33 20965780-10 2011 CONCLUSIONS: In patients with RLS-related mood disturbance, pramipexole improved RLS while also improving RLS-related mood impairment. Pramipexole 60-71 RLS1 Homo sapiens 81-84 20965780-10 2011 CONCLUSIONS: In patients with RLS-related mood disturbance, pramipexole improved RLS while also improving RLS-related mood impairment. Pramipexole 60-71 RLS1 Homo sapiens 81-84 20120624-11 2010 In the RLS treatment group, a statistically significant dose effect was found for pramipexole in those subjects confirmed to have ICDs by both the questionnaire and phone interview. Pramipexole 82-93 RLS1 Homo sapiens 7-10 18952497-0 2008 Effect of pramipexole on RLS symptoms and sleep: a randomized, double-blind, placebo-controlled trial. Pramipexole 10-21 RLS1 Homo sapiens 25-28 20161553-2 2009 The standard treatment recommendations for these disorders are pharmacologic; most recently both conditions are most typically managed with pramipexole or ropinerole, which are FDA approved for the treatment of RLS. Pramipexole 140-151 RLS1 Homo sapiens 211-214 19750232-8 2009 The first line treatment for idiopathic RLS is represented by dopamine agonists, in particular nonergot-derived ropinirole and pramipexole, whereas ergot dopamine agonists (cabergoline and pergolide) are no longer in first-line use given the risks of cardiac valvulopathy. Pramipexole 127-138 RLS1 Homo sapiens 40-43 20666116-3 2009 The dopamine agonists ropinirole and pramipexole are currently considered to be the agents of choice for the treatment of RLS. Pramipexole 37-48 RLS1 Homo sapiens 122-125 18952497-2 2008 Our goal was to test the ability of pramipexole to improve sleep in RLS patients and to reconfirm its efficacy for primary RLS symptoms. Pramipexole 36-47 RLS1 Homo sapiens 68-71 18952497-10 2008 CONCLUSIONS: Pramipexole is effective and well-tolerated for RLS and related sleep disturbance. Pramipexole 13-24 RLS1 Homo sapiens 61-64 16930379-4 2006 Amongst the non-ergoline dopamine agonists, pramipexole has been reported to reduce RLS symptoms, but robust trial data are limited. Pramipexole 44-55 RLS1 Homo sapiens 84-87 18611302-4 2008 Although two dopamine agonists, ropinirole and pramipexole, have been approved by the FDA for the treatment of RLS and are currently the first-line treatment for daily symptoms, there is very little information on the teratogenic risks of these new medications. Pramipexole 47-58 RLS1 Homo sapiens 111-114 18537487-9 2008 Several large, double-blind, placebo-controlled studies have demonstrated that dopamine agonists, such as ropinirole and pramipexole, are an efficacious first-line therapy for the treatment of RLS symptoms. Pramipexole 121-132 RLS1 Homo sapiens 193-196 14655914-2 2003 DESIGN: Retrospective review of the records of consecutive patients treated with pramipexole for RLS. Pramipexole 81-92 RLS1 Homo sapiens 97-100 17314491-1 2006 BACKGROUND: Pramipexole is a D3 dopaminergic agonist that has shown a major effect on both sensory and motor manifestations of restless legs syndrome (RLS) in long-term trials. Pramipexole 12-23 RLS1 Homo sapiens 151-154 17314491-3 2006 OBJECTIVE: To evaluate the acute effect of a low dosage of pramipexole (0.125 mg) on sensory symptoms and motor signs of RLS and on the macro- and microstructure of sleep. Pramipexole 59-70 RLS1 Homo sapiens 121-124 17314491-6 2006 Pramipexole 0.125 mg was administered before the second night at 9:00 p.m. A visual analog scale was used to assess the sensory symptoms of RLS. Pramipexole 0-11 RLS1 Homo sapiens 140-143 17314491-8 2006 RESULTS: After the acute administration of pramipexole, we observed a significant improvement of the sensory symptoms and motor signs of RLS. Pramipexole 43-54 RLS1 Homo sapiens 137-140 17314491-10 2006 CONCLUSIONS: Our results suggest that low doses of pramipexole are effective in reducing sensory symptoms and motor signs of RLS, even after the first administration. Pramipexole 51-62 RLS1 Homo sapiens 125-128 14655914-4 2003 PATIENTS: 60 consecutive patients treated with pramipexole for RLS. Pramipexole 47-58 RLS1 Homo sapiens 63-66 14655914-6 2003 MEASUREMENTS AND RESULTS: Pramipexole was completely effective in controlling RLS in 67%, partially effective in 27%, and ineffective in 7% of patients. Pramipexole 26-37 RLS1 Homo sapiens 78-81 14655914-14 2003 CONCLUSIONS: Pramipexole was effective for RLS with continued response with time. Pramipexole 13-24 RLS1 Homo sapiens 43-46 14521483-5 2003 Dopaminergic agents including levodopa and dopamine agonists such as pergolide, pramipexole, cabergoline and ropinirole are regarded as the treatment of choice for idiopathic RLS, however, the development of augmentation of symptoms, especially under levodopa therapy, may be a major problem. Pramipexole 80-91 RLS1 Homo sapiens 175-178 11346069-1 2001 OBJECTIVE: To review the use of newer dopamine agonists pramipexole and ropinirole, in the treatment of restless legs syndrome (RLS). Pramipexole 56-67 RLS1 Homo sapiens 128-131 11346069-4 2001 DATA SYNTHESIS: A number of small clinical studies of short duration have examined the use of pramipexole and ropinirole in the treatment of RLS. Pramipexole 94-105 RLS1 Homo sapiens 141-144 11346069-7 2001 CONCLUSIONS: Although the published trials show promising results for efficacy of pramipexole and ropinirole in the treatment of RLS, they are subject to many limitations. Pramipexole 82-93 RLS1 Homo sapiens 129-132